Stock Ratings / Health Care / ALLR / dividends

BFRI (40) OPTH (49) DARE (44) CTXR (49) ⌘ Pro Terminal →

Allarity Therapeutics Inc. (ALLR) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.89 -6.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Allarity Therapeutics Inc. (ALLR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $14.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALLR)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALLR)

✓Walkthrough of ALLR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALLR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.07%▼ DESCENDING CHANNEL

2026-10-30O $0.89H $0.90L $0.85C $0.89VOL 178.6K

RES: $1.28SUP: $0.76SMA50: $1.10SMA200: $1.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALLR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALLR Butterfly Map → + Track ALLR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALLR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALLR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALLR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALLR)

Health Care Rank #728 of 1016 ⚔️ BFRI vs ALLR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALLR vs. BFRI, OPTH, DARE, CTXR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Allarity Therapeutics Inc. (ALLR) ranks #728 by composite RQD confidence (38/100, grade D-) and #861 by equity capitalization ($14.2M). Within this direct 5-issuer industry benchmark cohort, ALLR leads on earnings valuation at N/A trailing P/E, while ALLR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OPTH currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ALLR at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALLR ACTIVE Allarity Therapeutics Inc.	D-	38/100	—	—	-35.0%	-6.32%	$14.2M	Benchmark Subject
BFRI Biofrontera Inc.	D-	40/100	—	—	-35.0%	+5.09%	$13.8M	/bfri-vs-allr →
OPTH Optimi Health Corp.	D	49/100	—	—	—	-6.81%	$14.9M	/opth-vs-allr →
DARE Dare Bioscience Inc.	D	44/100	—	71.3%	-35.0%	+0.22%	$13.4M	/dare-vs-allr →
CTXR Citius Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+4.07%	$15.5M	/ctxr-vs-allr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001860657

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Allarity Therapeutics Inc. (ALLR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.2M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (+16.0% YoY). On the balance sheet, ALLR closed FY2025 with $18.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.2M	-$14.8M	-$14.8M	$18.3M	—
FY2024 (FY)	2024-12-31	$0	-$24.5M	-$17.4M	-$17.6M	$22.6M	—
FY2023 (FY)	2023-12-31	$0	-$11.9M	-$12.7M	-$12.7M	—	—

3. ALLR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Allarity Therapeutics Inc. (NASDAQ: ALLR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.89 (-6.32% 1D, market cap $14.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALLR ranks #728 in composite RQD confidence.

How does ALLR compare to BFRI and OPTH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALLR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BFRI (Biofrontera Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M) and OPTH (Optimi Health Corp.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $14.9M). Among the 5-stock peer group, ALLR leads on earnings multiple (N/A) while ALLR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALLR?

Per ALLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860657), Allarity Therapeutics Inc. generated $0 in revenue, -$11.2M in net income, and -$14.8M in free cash flow against $18.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALLR trading relative to its 50-day, 200-day, and 52-week technical levels?

ALLR last traded at $0.89 (-6.32% on volume of 150,076 shares), positioning the stock -19.09% below its 50-day simple moving average ($1.10) and -27.05% below its 200-day simple moving average ($1.22). Across its 52-week range of $0.77 to $1.84, ALLR sits at the 11.2% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.00).

ALLR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ALLR pay a dividend and is it safe?

Allarity Therapeutics Inc. (ALLR) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ALLR RQD Cockpit ALLR 12M Forecast ALLR Earnings & Move ALLR Dividends & DRIP ALLR Insiders & 13F ALLR Whale Options ALLR Profit Sankey ALLR News & Why